Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.

NVCT·NASDAQ

$9.42

-0.95%
HealthcareBiotechnology

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

At a Glance

Live Snapshot
Market Cap$249.87M
EPS-1.3200
P/E Ratio-7.14
Earnings Date08/04/2026

nvct

Free Cash Flow

Last Annual Value

-16.01M

3-Year CAGR

-6%

5-Year CAGR

%

10-Year CAGR

%

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Competitors Analysis of Free Cash Flow

NVCT · NASDAQ
CompanyFree Cash Flow
CAGR 3Y
CAGR 5Y
CAGR 10Y
-16.01M
N/AN/AN/A 
-51.79M
N/AN/AN/A
-99.30M
N/AN/AN/A
PEPG logo
PepGen Inc.
NASDAQ:PEPG
-81.90M
N/AN/AN/A
-19.21M
N/AN/AN/A
-29.79M
N/AN/AN/A
-9.91M
N/AN/AN/A
-12.00M
N/AN/AN/A
-37.97M
N/AN/AN/A
-18.80M
N/AN/AN/A
-103.21M
N/AN/AN/A
Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Fair Value Envelope

NVCT · NASDAQ

Our analysis suggests that NVCT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.42, this represents a potential HIDDEN relative to our calculated worth for Nuvectis Pharma, Inc..

Intrinsic Value
Current Price: $9.42